Irritable Bowel Syndrome Clinical Trial
— FOSIILOfficial title:
Efficacy of a Low FODMAP Diet According to Colonic pH Measured by Wireless Motility Capsule in Irritable Bowel Syndrome Patients
Treatments efficacy in irritable bowel syndrome (IBS) patients is inconstant and predictive factors of their efficacy are needed. The role of dysbiosis in IBS is well-known. Another way to identify microbiota differences is to assess its metabolic activity. It has been demonstrated that colonic pH in IBS patients is lower than in healthy volunteers, reflecting a highest colonic fermentation. Colonic acidification is able to sensitize colonic mechano-receptors to distension. Microbiota profile is able to predict the response to a low Fermentable Oligo, Di, Monosaccharides And Polyols (FODMAPs) diet, but is not available in clinical routine. The aim of our study is to assess the link between colonic fermentation (measured by colonic pH) and the efficacy of a low FODMAPs diet in IBS patients (measured by IBS severity scoring system (IBS-SSS)). We hypothesis that IBS patients with a lower colonic pH will have a better efficacy of the low FODMAPs diet. It might allow in the future personalized medicine. 50 IBS patients according to Rome IV criteria will be included in our study. All patients will have a measure of their colonic pH by wireless motility capsule. Patients will follow a low FODMAPs diet for 6 weeks after an education by a trained dietician. All participants will fill validated questionnaires before and after 6 weeks of low FODMAPs diet: IBS-SSS, Gastro Intestinal Quality of Life Index (GIQLI), Hospital Anxiety and Depression (HAD) scale. Microbiota, metabolomic and short chain fatty acid will be analysed before and after the intervention. The number of patients was calculated to assess the correlation between colonic pH and the variation of IBS-SSS before and after the intervention.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | August 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - IBS according to Rome IV criteria - Normal blood test (cell blood count, C Reactive Protein, thyroid-stimulating hormone, anti transglutaminase antibodies) in the last 12 months - IBS severity score (IBS-SSS) >175/500 - IBS treatments stable in the last month - Effective contraception since 1 month for women in childbearing age Exclusion Criteria: - Anorexia nervosa or any eating disorders deemed incompatible - Organic gastroenterological diseases (inflammatory bowel disorder, microscopic colitis, gastrointestinal cancer, celiac disease) - Contra-indication to the wireless motility capsule (intestinal stenosis, digestive fistula or obstruction, history of bezoar, gastrointestinal surgery in the last 3 months, acute diverticulitis, cardiac pacemaker, implanted electromedical device, magnetic resonance imaging planned in the 5 days after the wireless motility capsule, swallowing disorder) - Breastfeeding or pregnant women - Participation in another clinical trial in the last 2 weeks - Patient who could not stop proton pump inhibitor treatment for 10 days - Person with administrative or judicial decision or under legal protection measure |
Country | Name | City | State |
---|---|---|---|
France | Rouen University Hospital | Rouen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Rouen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Correlation between efficacy of the low FODMAP diet on severity and the colonic pH | Correlation between colonic pH (baseline) and the variation of IBS severity score (IBS-SSS). IBS-SSS is a score between 0 (no symptom) to 500 (highest symptom level). | 6 weeks | |
Secondary | Correlation between efficacy of the low FODMAP diet on quality of life and the colonic pH | Correlation between colonic pH (baseline) and variation of the quality of life Index (GIQLI). GIQLI is a score between 0 (lowest quality of life) and 144 (best quality of life). | 6 weeks | |
Secondary | Correlation between efficacy of the low FODMAP diet on stool frequency and the colonic pH | Correlation between colonic pH (baseline) and variation of the stool frequency | 6 weeks | |
Secondary | Correlation between efficacy of the low FODMAP diet on stool consistency and the colonic pH | Correlation between colonic pH (baseline) and variation of the stool consistency (BSF) | 6 weeks | |
Secondary | Correlation between efficacy of the low FODMAP diet on anxiety and the colonic pH | Correlation between colonic pH (baseline) and variation of anxiety (HAD). HAD anxiety is a scale comprised between 0 (no anxiety) and 21 (highest anxiety). | 6 weeks | |
Secondary | Correlation between efficacy of the low FODMAP diet on depression and the colonic pH | Correlation between colonic pH (baseline) and variation of depression (HAD). HAD depression is a scale comprised between 0 (no depression) and 21 (highest depression). | 6 weeks | |
Secondary | Correlation between short chain fatty acids and the colonic pH | Correlation between colonic pH (baseline) and variation of short chain fatty acids (in the stool) | 6 weeks | |
Secondary | Correlation between metabolites and the colonic pH | Correlation between colonic pH (baseline) and variation of metabolites (in the stool). Among metabolites, short chain fatty acids, 28 biliary acids and lipopeptides (C12-GABA, C12-Glutamine, C14-Glutamine, C15-GABA, C16-Glutamate, C16-Glutamine, C18-GABA, C12:1-Alanine (Ala)-GABA, C12-Ala-GABA, C13-Ala-GABA, C14:1-Ala-GABA et C183OH-Glutamate-GABA) will be assessed. Metabolites will be also assessed by RMN spectroscopy that allow the assessment of a high ranges of different metabolites. | 6 weeks | |
Secondary | Colonic pH according to small intestinal bacterial overgrowth | Comparison of colonic pH between patients with and without small intestinal bacterial overgrowth | baseline | |
Secondary | Colonic pH according to fructose malabsorption | Comparison of colonic pH between patients with and without fructose malabsorption | baseline | |
Secondary | Colonic pH according to visceral hypersensitivity | Comparison of colonic pH between patients with and without visceral hypersensitivity | Baseline | |
Secondary | Colonic pH and fecal calprotectin | Correlation between colonic pH and fecal calprotectin | Baseline | |
Secondary | Colonic pH and rectal pain threshold | Correlation between colonic pH and rectal pain threshold | Baseline | |
Secondary | Correlation between baseline QOL and the colonic pH | Correlation between colonic pH and baseline GIQLI (quality of life Index) | Baseline | |
Secondary | Correlation between baseline IBS severity score and colonic pH | Correlation between colonic pH and baseline IBS severity score (IBS-SSS) | Baseline | |
Secondary | Correlation between baseline anxiety and colonic pH | Correlation between colonic pH and baseline anxiety (HAD) | Baseline | |
Secondary | Correlation between baseline depression and colonic pH | Correlation between colonic pH and baseline depression (HAD) | Baseline | |
Secondary | Correlation between baseline stool consistency and colonic pH | Correlation between baseline stool consistency (BSF) and colonic pH | Baseline | |
Secondary | Correlation between baseline stool frequency and colonic pH | Correlation between baseline stool frequency and colonic pH | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |